The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis
Objectives: Irritable bowel syndrome (IBS) affects 10-15% of the population, and treatment options are limited. Rifaximin is a minimally absorbed antibiotic that has shown efficacy in IBS patients. The objective of our study was to perform a meta-analysis and systematic review of available randomize...
Saved in:
Main Authors: | Stacy B. Menees, Monthira Maneerattannaporn, Hyungjin Myra Kim, William D. Chey |
---|---|
Other Authors: | A. Alfred Taubman Health Care Center |
Format: | Review |
Published: |
2018
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/15078 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Emerging Pharmacological Therapies for the Irritable Bowel Syndrome
by: Monthira Maneerattanaporn, et al.
Published: (2018) -
Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome
by: William D. Chey, et al.
Published: (2018) -
The association between irritable bowel syndrome and osteoporosis: a systematic review and meta-analysis
by: W. Wongtrakul, et al.
Published: (2020) -
Pathophysiology of Irritable Bowel Syndrome
by: Rastita Widyasari, et al.
Published: (2017) -
Increased prevalence of irritable bowel syndrome in migraine patients: a systematic review and meta-analysis
by: Wasit Wongtrakul, et al.
Published: (2022)